Follow-on treatment study for dabrafenib and trametinib
Treatments studied
Part of Cancer, Lungs & breathing, Skin clinical trials.
This study lets people who finished a prior dabrafenib/trametinib trial (sponsored by Novartis or former GSK) continue those medicines if the study doctor thinks it will help. It mainly focuses on ongoing treatment benefit rather than testing a new drug.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are currently taking dabrafenib and/or trametinib as part of a completed Novartis or former GSK study.
- That earlier study must have met its main study goals (primary objective).
- Your study doctor believes you would benefit from continuing treatment.
- You were not permanently taken off the study medicines in the original (parent) study.
- You do not have any ongoing, unresolved side effects that caused your dabrafenib/trametinib doses to be paused in the original study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized approach where doctors monitor tumor DNA in your blood to decide when to pause targeted therapy (encorafenib and binimetinib) for advanced melanoma with a BRAF mutation. The goal is to see if treatment breaks can be safe and effective.
This Phase 1 trial studies PF-07799933, a new medicine, in people whose advanced solid tumors have specific BRAF genetic changes. It may help if your cancer has continued to grow after standard treatments, and there may be specific options depending on your cancer type and past therapies.
This trial tests a new drug called BI 3810944 for people with advanced solid tumors that haven't responded to standard treatments. It aims to see if the drug is safe and helps shrink tumors.
This study checks on the long-term health of adults with melanoma who took part in a previous treatment study. It aims to see how participants are doing over time after receiving the new therapy.
This trial tests a combination of targeted therapy (dabrafenib and trametinib) and immunotherapy (nivolumab) for children and young adults with certain BRAF gene changes in their glioma. It aims to see if this drug combination can shrink tumors or stop them from growing.
This study lets people who previously took encorafenib and binimetinib continue those same medicines if they are benefiting and side effects are not severe. It’s meant to help participants stay on treatment safely while the original trial is completed.
Hear when a new Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.